JP

Jitendra Patel

Active Director Director DIN 08774665
DIN 08774665 First appointment Jun 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2020
Shareholding value •••• Premium profile

About Jitendra Patel

Data last updated:

Jitendra Patel is a Director at Jrp Drugs Private Limited (since 2020). The company operates in Pharma. Jrp Drugs Private Limited reported revenue of ₹66.3 Lakh (FY 2025).

DIN 08774665
Primary Designation Director
Industry Pharma
First Appointment 28 Jun 2020
Oldest Company Age 6 yrs
Largest company Jrp Drugs Private Limited · ₹66.3 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Jrp Drugs Private Limited U51909CT2020PTC010199
Director28 Jun 20202020₹66.3 Lakh (FY 2025)Active

Board colleagues of Jitendra Patel

NameDINCompanyDesignation
Romit Patel08774666Jrp Drugs Private LimitedDirector

Directorship timeline

Open interactive timeline →
Jrp Drugs Private Limited
Premium access

Shareholding and investment profile for Jitendra Patel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jitendra Patel

Jitendra Patel currently holds 1 directorship: Jrp Drugs Private Limited (Director, since 28 Jun 2020, revenue ₹66.3 Lakh (FY 2025)).

Jitendra Patel was first appointed on 28 Jun 2020 as Director at Jrp Drugs Private Limited.

The current boards of Jitendra Patel's companies include Romit Patel (Jrp Drugs Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available